195 related articles for article (PubMed ID: 30779990)
21. Cross-walk of the Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH) and the EuroQol EQ-5D-5L in patients with NASH.
Fishman J; Higgins V; Piercy J; Pike J
Health Qual Life Outcomes; 2023 Oct; 21(1):113. PubMed ID: 37838660
[TBL] [Abstract][Full Text] [Related]
22. Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes.
Younossi ZM; Wong VW; Anstee QM; Romero-Gomez M; Trauner MH; Harrison SA; Lawitz EJ; Okanoue T; Camargo M; Kersey K; Myers RP; Goodman Z; Stepanova M
Hepatol Commun; 2020 Nov; 4(11):1637-1650. PubMed ID: 33163834
[TBL] [Abstract][Full Text] [Related]
23. Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis.
Wong RJ; Tran T; Kaufman H; Niles J; Gish R
PLoS One; 2019; 14(8):e0220612. PubMed ID: 31369606
[TBL] [Abstract][Full Text] [Related]
24. Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis.
Younossi ZM; Stepanova M; Nader F; Loomba R; Anstee QM; Ratziu V; Harrison S; Sanyal AJ; Schattenberg JM; Barritt AS; Noureddin M; Bonacci M; Cawkwell G; Wong B; Rinella M;
Clin Gastroenterol Hepatol; 2022 Sep; 20(9):2050-2058.e12. PubMed ID: 34274514
[TBL] [Abstract][Full Text] [Related]
25. Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis.
Méndez-Sánchez N; Cerda-Reyes E; Higuera-de-la-Tijera F; Salas-García AK; Cabrera-Palma S; Cabrera-Álvarez G; Cortez-Hernández C; Pérez-Arredondo LA; Purón-González E; Coronado-Alejandro E; Panduro A; Rodríguez-Hernández H; Cruz-Ramón VC; Valencia-Rodríguez A; Qi X; Hamdan-Pérez N; Aguilar-Olivos NE; Barranco-Fragoso B; Ramírez-Pérez O; Vera-Barajas A
F1000Res; 2020; 9():56. PubMed ID: 32595949
[No Abstract] [Full Text] [Related]
26. Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey.
Wong RJ; Liu B; Bhuket T
Aliment Pharmacol Ther; 2017 Nov; 46(10):974-980. PubMed ID: 28914448
[TBL] [Abstract][Full Text] [Related]
27. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.
Musso G; Cassader M; Paschetta E; Gambino R
JAMA Intern Med; 2017 May; 177(5):633-640. PubMed ID: 28241279
[TBL] [Abstract][Full Text] [Related]
28. Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials.
Wong VW; Tak WY; Goh GBB; Cheng PN; Lawitz EJ; Younossi ZM; Vuppalanchi R; Younes Z; Alkhouri N; Wang L; Liu J; Kersey K; Myers RP; Harrison SA; Goodman Z; Trauner M; Romero-Gomez M; Anstee QM; Nguyen MH; Okanoue T
Clin Gastroenterol Hepatol; 2023 Jan; 21(1):90-102.e6. PubMed ID: 35074532
[TBL] [Abstract][Full Text] [Related]
29. Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis.
McSweeney L; Breckons M; Fattakhova G; Oluboyede Y; Vale L; Ternent L; Balp MM; Doward L; Brass CA; Beyer F; Sanyal A; Anstee QM
JHEP Rep; 2020 Jun; 2(3):100099. PubMed ID: 32435754
[TBL] [Abstract][Full Text] [Related]
30. Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study.
O'Hara J; Finnegan A; Dhillon H; Ruiz-Casas L; Pedra G; Franks B; Morgan G; Hebditch V; Jönsson B; Mabhala M; Reic T; Van Thiel I; Ratziu V; Romero-Gomez M; Bugianesi E; Schattenberg JM; Anstee QM
JHEP Rep; 2020 Oct; 2(5):100142. PubMed ID: 32775976
[TBL] [Abstract][Full Text] [Related]
31. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.
Leite NC; Villela-Nogueira CA; Pannain VL; Bottino AC; Rezende GF; Cardoso CR; Salles GF
Liver Int; 2011 May; 31(5):700-6. PubMed ID: 21457442
[TBL] [Abstract][Full Text] [Related]
32. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.
Sanyal AJ; Harrison SA; Ratziu V; Abdelmalek MF; Diehl AM; Caldwell S; Shiffman ML; Aguilar Schall R; Jia C; McColgan B; Djedjos CS; McHutchison JG; Subramanian GM; Myers RP; Younossi Z; Muir AJ; Afdhal NH; Bosch J; Goodman Z
Hepatology; 2019 Dec; 70(6):1913-1927. PubMed ID: 30993748
[TBL] [Abstract][Full Text] [Related]
33. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
[TBL] [Abstract][Full Text] [Related]
34. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
[TBL] [Abstract][Full Text] [Related]
35. Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™.
Younossi ZM; Yu ML; Yilmaz Y; Alswat KA; Buti M; Fernandez MIC; Papatheodoridis G; Hamid SS; El-Kassas M; Chan WK; Duseja AK; Gordon SC; Eguchi Y; Isakov VA; Roberts SK; Fan JG; Singal AK; Romero-Gómez M; Ahmed A; Ong J; Lam BP; Younossi I; Nader F; Racila A; Stepanova M; Alqahtani S
J Viral Hepat; 2023 Apr; 30(4):335-344. PubMed ID: 36601668
[TBL] [Abstract][Full Text] [Related]
36. Histologic Scores for Fat and Fibrosis Associate With Development of Type 2 Diabetes in Patients With Nonalcoholic Fatty Liver Disease.
Björkström K; Stål P; Hultcrantz R; Hagström H
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1461-1468. PubMed ID: 28479500
[TBL] [Abstract][Full Text] [Related]
37. Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis-4 Score.
Gordon SC; Kachru N; Parker E; Korrer S; Ozbay AB; Wong RJ
Hepatol Commun; 2020 Jul; 4(7):998-1011. PubMed ID: 32626832
[TBL] [Abstract][Full Text] [Related]
38. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
[TBL] [Abstract][Full Text] [Related]
39. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany.
Labenz C; Huber Y; Kalliga E; Nagel M; Ruckes C; Straub BK; Galle PR; Wörns MA; Anstee QM; Schuppan D; Schattenberg JM
Aliment Pharmacol Ther; 2018 Nov; 48(10):1109-1116. PubMed ID: 30288767
[TBL] [Abstract][Full Text] [Related]
40. The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.
Younossi Z; Stepanova M; Sanyal AJ; Harrison SA; Ratziu V; Abdelmalek MF; Diehl AM; Caldwell S; Shiffman ML; Schall RA; McColgan B; Subramanian GM; Myers RP; Muir A; Afdhal NH; Bosch J; Goodman Z
J Hepatol; 2018 Dec; 69(6):1365-1370. PubMed ID: 30144554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
